Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.66 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.66 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8318203 | 0.93 | GAA (0.58) | S1PR5S1PR1GAANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL8324757 | 0.92 | GAA (0.57) | S1PR5S1PR1MAOBGAANPC1 | |
| SCHEMBL6284121 | 0.87 | GAA (0.63) | S1PR5S1PR1GAANPC1RAB9A | |
| SCHEMBL6286609 | 0.87 | GAA (0.63) | S1PR5S1PR1GAANPC1RAB9A | |
| SCHEMBL2450749 | 0.87 | GAA (0.63) | S1PR5S1PR1GAANPC1RAB9A | |
| SCHEMBL565212 | 0.85 | S1PR5 (0.87) | S1PR5S1PR1FUCA1 | |
| SCHEMBL3314498 | 0.84 | GAA (0.77) | GAANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL2444402 | 0.84 | GAA (0.77) | GAANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL2330642 | 0.84 | S1PR5 (0.68) | S1PR5S1PR1FUCA1KDM4EALDH1A1 | |
| SCHEMBL518686 | 0.83 | NPC1 (0.71) | GAANPC1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | claimed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | PIK3CA, PIK3CB, PIK3CG | S1PR5 871/4885S1PR1 1015/4885MAOB 3315/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | S1PR5 1812/4885S1PR1 1379/4885MAOB 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.